Low-Grade Gliomas also called astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still suffer from the effects of a tumor, which may result in higher rates of morbidity and mortality. The available treatment options for children are limited in recurrent and/or disseminated, or circulated tumors, as well as those with tumors not suited for surgical resection. To date, this significant, un-met need for more effective, targeted therapeutics for children with unresectable or progressive astrocytomas has not yet been satisfied.
Available CBTN Biospecimens
participants with flash-frozen tissue available
participants with match blood
participants with match parental specimens
participants with cerebral spinal fluid
Available CBTN Pre-clinical Models
genomically characterized cell lines with data available
genomically characterized pdx with data available
Explore the data in these informatics portals
How do I get access to the data?
To access the data please follow these instructions. Need help? Contact us at email@example.com
You can access processed data today here by simply logging in to PedcBioPortal
You can request raw data by completing this form. The review normally takes 1 week. Once approved you can access the raw data by creating cohorts of interest on the Kids First Data Resource Portal and performing analysis on the cloud in Cavatica
Delineating Pediatric Glioma Progression Using Single-nuclei Sequencing
Low grade gliomas are the most prevalent brain cancer among children and deeper study is needed to steer treatment protocol for patients that experience recurrence. Using samples provided by the Children’s Brain Tumor Network, researchers hope to better understand this disease and to identify new therapies.
Exploration of IDO1 as a Therapeutic Target in Pediatric Central Nervous System Tumors
Recent work points to the enzyme IDO1 as a high value target for the treatment of adult glioma. Researchers will analyze samples provided by the Children’s Brain Tumor Network to determine whether IDO1 could serve as a therapeutic target for pediatric brain tumors as well.
Medulloblastoma, HGG, LGG, Ependymoma, DIPG
Rishi Ramesh Lulla
Investigating the Immune Response in Pediatric Glioma Subsets
Preliminary analysis of data on the immune response of pediatric low grade glioma shows promising leads for treatment prioritization. Using data from the Pediatric Brain Tumor Atlas, researchers will deepen this analysis on a larger dataset.